Answers are grounded in this paper and cite their sources.
Despite the progress made in understanding the biology of autism spectrum disorder (ASD), effective biological interventions for the core symptoms remain elusive. Because of the etiological heterogeneity of ASD, identification of a "one-size-fits-all" treatment approach will likely continue to be challenging. A meeting was convened at the University of Missouri and the Thompson Center to discuss strategies for stratifying patients with ASD for the purpose of moving toward precision medicine. The "white paper" presented here articulates the challenges involved and provides suggestions for future solutions.
No takes yet. Share an insight, caveat, or question.
David Q. Beversdorf (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: